These studies will hopefully inform the therapeutic utility of HIF2α inhibitors for advanced PPGL as well as tumours harbouring EPAS1, VHL, SDHX, FH and other somatic and germline ‘Cluster 1’ gene mutations. This evidence concerns the gene EPAS1 and neoplasm.